{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T02:55:02Z","timestamp":1755226502893,"version":"3.43.0"},"reference-count":40,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>The liver is crucial for metabolizing the anticancer drug palbociclib, but limited information is available on the impact of hepatic impairment on its toxicity and efficacy, with no real\u2010world data available. This study aims to evaluate how hepatic impairment affects hematological toxicity and progression\u2010free survival (PFS) of palbociclib in advanced hormone receptor\u2010positive\/human epidermal growth factor receptor 2\u2010negative breast cancer, using the National Cancer Institute scoring system, in a large real\u2010world dataset. This multicenter retrospective observational study included female patients treated with palbociclib between August 2017 and February 2024. Regression analysis was used to compare the risk of developing grade 3\/4 hematological toxicity and PFS between patients with normal and mild impaired liver function. In total, 478 female patients were included. Patients with mild hepatic impairment (<jats:italic>n<\/jats:italic>\u2009=\u2009205) did not have an increased risk of developing grade 3\/4 neutropenia compared with patients with normal hepatic function (<jats:italic>n<\/jats:italic>\u2009=\u2009273) (hazard ratio (HR)\u2009=\u20091.11; 95% CI 0.83\u20131.47). In addition, the PFS was not significantly different between both groups (HR\u2009=\u20091.15; 95% CI 0.93\u20131.42). In real\u2010world settings, patients with mild hepatic impairment do not have a higher risk of developing palbociclib\u2010induced neutropenia or disease progression than patients with normal hepatic function. These findings can guide clinicians when treating breast cancer patients with mild hepatic impairment.<\/jats:p>","DOI":"10.1002\/cpt.3574","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T22:59:40Z","timestamp":1737759580000},"page":"1115-1122","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Palbociclib Is Safe for Breast Cancer Patients With Mild Hepatic Impairment: A Multicenter Retrospective Study Using Real\u2010World Data"],"prefix":"10.1002","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9791-0070","authenticated-orcid":false,"given":"Alieke K.","family":"Bos","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy Tergooi Medical Centre  Hilversum The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2433-1915","authenticated-orcid":false,"given":"Annelieke E.C.A.B.","family":"Willemsen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Tergooi Medical Centre  Hilversum The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1421-6246","authenticated-orcid":false,"given":"Loes E.","family":"Visser","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Haga Teaching Hospital  The Hague The Netherlands"},{"name":"Department of Hospital Pharmacy Erasmus Medical Centre  Rotterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6992-8964","authenticated-orcid":false,"given":"Lennart J.","family":"Stoker","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Haaglanden Medical Centre  The Hague The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5115-3275","authenticated-orcid":false,"given":"Jurjen S.","family":"Kingma","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Hospital Group Twente  Almelo and Hengelo The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjam K.","family":"Rommers","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Noordwest\u00a0Ziekenhuisgroep  Alkmaar The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6148-7397","authenticated-orcid":false,"given":"Emile M.","family":"Kuck","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy Diakonessenhuis  Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1564-2041","authenticated-orcid":false,"given":"Paul D.","family":"van der Linden","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Tergooi Medical Centre  Hilversum The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1763-7334","authenticated-orcid":false,"given":"Merel","family":"van Nuland","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Tergooi Medical Centre  Hilversum The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"e_1_2_10_1_1","unstructured":"European Medicines Agency.Summary of Product Characteristics Ibrance<https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/ibrance\u2010epar\u2010product\u2010information_en.pdf> (2021). Accessed October 10 2024."},{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13684"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01263-0"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/1178223418823238"},{"key":"e_1_2_10_5_1","unstructured":"U.S. Food and Drug Administration.Clinical Pharmacology and Biopharmaceutics Review(s) Ibrance<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/207103orig1s000clinpharmr.pdf> (2014). Accessed October 10 2024."},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.902"},{"key":"e_1_2_10_7_1","unstructured":"U.S. Department of Health and Human Services.Common Terminology Criteria for Adverse Events (CTCAE) Version 5<https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf> (2017). Accessed October 10 2024."},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30145-7"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1702"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70279-1"},{"key":"e_1_2_10_11_1","unstructured":"European Medicines Agency.Guideline on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Impaired Hepatic Function<https:\/\/www.ema.europa.eu\/en\/evaluation\u2010pharmacokinetics\u2010medicinal\u2010products\u2010patients\u2010impaired\u2010hepatic\u2010function\u2010scientific\u2010guideline> (2005). Accessed October 10 2024."},{"key":"e_1_2_10_12_1","unstructured":"U.S. Food and Drug Administration.Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design Data Analysis and Impact on Dosing and Labeling<https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/pharmacokinetics\u2010patients\u2010impaired\u2010hepatic\u2010function\u2010study\u2010design\u2010data\u2010analysis\u2010and\u2010impact\u2010dosing\u2010and> (2018). Accessed October 10 2024."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100162"},{"key":"e_1_2_10_14_1","unstructured":"U.S. Department of Health and Human services.Protocol Templates for Organ Dysfunction Studies<https:\/\/ctep.cancer.gov\/protocoldevelopment\/templates_applications.htm> (2024). Accessed October 10 2024."},{"key":"e_1_2_10_15_1","unstructured":"European Medicines Agency.Ibrance: Procedural steps taken and scientific information after the authorisation<https:\/\/www.ema.europa.eu\/en\/documents\/procedural\u2010steps\u2010after\/ibrance\u2010epar\u2010procedural\u2010steps\u2010taken\u2010scientific\u2010information\u2010after\u2010authorisation_en.pdf> (2024). Accessed December 7 2024."},{"key":"e_1_2_10_16_1","unstructured":"CTcue B.V.Empowering healthcare with real\u2010world data evidence<https:\/\/ctcue.com\/> (2024). Accessed December 7 2024."},{"key":"e_1_2_10_17_1","unstructured":"National Health Care Institute.Reimbursement recommendation for the drug Palbociclib (Ibrance\u00ae) for patients with locally advanced or metastatic breast cancer<https:\/\/www.zorginstituutnederland.nl\/publicaties\/adviezen\/2017\/04\/11\/pakketadvies\u2010palbociclib> (2024). Accessed December 2 2024."},{"key":"e_1_2_10_18_1","unstructured":"Royal Dutch Pharmacists Association.Interaction lists<https:\/\/kennisbank.knmp.nl\/article\/Informatorium_Medicamentorum\/G1126.html#G2055> (2024). Accessed December 7 2024."},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2023.100691"},{"key":"e_1_2_10_20_1","unstructured":"Cleveland Clinic.Sample size calculator<https:\/\/riskcalc.org\/samplesize\/> Accessed October 10 2023."},{"volume-title":"Flexible Imputation of Missing Data","year":"2021","author":"Buuren S.","key":"e_1_2_10_21_1"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X211027181"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07400-z"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102810"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-024-02893-z"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11764-8"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/15330338221132926"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12941-z"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4301"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0967-7"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.1543"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00930-x"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0019"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0097"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99504-5"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.201900347"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4606-9"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-018-0958-2"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000001808"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09624-y"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.3574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T09:21:43Z","timestamp":1754904103000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.3574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1002\/cpt.3574"],"URL":"https:\/\/doi.org\/10.1002\/cpt.3574","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"type":"print","value":"0009-9236"},{"type":"electronic","value":"1532-6535"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"2024-10-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}